简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Nutriband通过逮捕令筹集175万美元以推进AVERSA芬太尼

2026-10-13 20:38

  • Nutriband (NTRB) received $1.75M from the exercise of 272,671 NTRBW warrants at $6.43 per share.
  • The NTRBW warrants expired on September 30, with no extension, leaving the company with no remaining tradeable warrants.
  • Proceeds will primarily fund the remaining clinical development of AVERSA Fentanyl and the preparation and submission of its new drug application to the FDA.
  • AVERSA Fentanyl aims to become the world’s first opioid patch with abuse-deterrent properties.
  •  The company estimates that AVERSA Fentanyl could achieve peak annual U.S. sales of $80M to $200M.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。